Regeneron Pharmaceuticals (REGN) to Release Quarterly Earnings on Tuesday

Regeneron Pharmaceuticals (NASDAQ:REGN) is expected to issue its Q3 2025 results before the market opens on Tuesday, October 28th. Analysts expect the company to announce earnings of $9.73 per share and revenue of $3.5712 billion for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Tuesday, October 28, 2025 at 8:30 AM ET.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating the consensus estimate of $8.43 by $4.46. The company had revenue of $3.68 billion during the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The business’s revenue was up 3.6% compared to the same quarter last year. During the same period in the prior year, the company earned $11.56 earnings per share. On average, analysts expect Regeneron Pharmaceuticals to post $36 EPS for the current fiscal year and $38 EPS for the next fiscal year.

Regeneron Pharmaceuticals Stock Down 0.2%

NASDAQ:REGN opened at $576.77 on Tuesday. The firm has a market capitalization of $61.13 billion, a PE ratio of 14.54, a price-to-earnings-growth ratio of 1.80 and a beta of 0.31. The stock has a 50 day moving average of $575.25 and a 200-day moving average of $562.14. Regeneron Pharmaceuticals has a 52 week low of $476.49 and a 52 week high of $991.23. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were given a dividend of $0.88 per share. The ex-dividend date was Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s payout ratio is currently 8.87%.

Institutional Trading of Regeneron Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Banque Transatlantique SA grew its holdings in Regeneron Pharmaceuticals by 105.4% during the 2nd quarter. Banque Transatlantique SA now owns 304 shares of the biopharmaceutical company’s stock worth $160,000 after acquiring an additional 156 shares during the period. MUFG Securities EMEA plc acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth $161,000. Dynamic Technology Lab Private Ltd acquired a new stake in Regeneron Pharmaceuticals during the 1st quarter worth $226,000. Paces Ferry Wealth Advisors LLC grew its holdings in Regeneron Pharmaceuticals by 5.4% during the 2nd quarter. Paces Ferry Wealth Advisors LLC now owns 548 shares of the biopharmaceutical company’s stock worth $288,000 after acquiring an additional 28 shares during the period. Finally, Scott Marsh Financial LLC acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth $303,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

REGN has been the subject of a number of research analyst reports. Royal Bank Of Canada upped their target price on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a “sector perform” rating in a research report on Monday, August 4th. Guggenheim boosted their target price on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Argus downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, June 30th. BMO Capital Markets raised their price target on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an “outperform” rating in a research report on Monday, August 4th. Finally, Jefferies Financial Group increased their target price on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a “buy” rating in a research note on Wednesday, August 27th. Three research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $817.88.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.